Latest Conference Coverage

Despite Slight Differences, Preventive Migraine Therapies Demonstrate High Efficacy

Researchers used a connected network of studies that were generally well balanced in terms of key baseline characteristics, such as baseline MMD and use of prior therapies, to compare preventive treatments.

NeuroVoices: Andrew Blumenfeld, MD, on a Combination Approach to Treating Chronic Migraine

The director for the Headache Center of Southern California discussed his research presented at AHS 2021 which evaluated a combination of onabotunlinumtoxinA and CGRPs in patients with chronic migraine.

Fremanezumab Yields Monthly Migraine and Headache Reductions in Real-World Setting

Recent data presented at the AHS annual meeting showed clinically meaningful improvements in MMD and MHD in patients with both chronic and episodic migraine.

No Significant Wearing Off Effect With Galcanezumab for Migraine Prevention

A post-hoc analysis of 4 clinical trials of galcanezumab found no differences between dose groups of galcanezumab or placebo in rates of ‘wearing off’ effect.

Applying Data on CGRP, OnabotulinumtoxinA Combination to Clinical Practice: Andrew Blumenfeld, MD

The director of the Headache Center of Southern California provided insight on how a layered treatment approach to chronic migraine can be directly implemented into clinical care.

Advantages of Migraine Buddy App: Richard B. Lipton, MD

The director of the Montefiore Headache Center detailed the ways the Migraine Buddy app can help simplify conducting migraine clinical trials while expanding the reach of patients.

Ubrogepant Demonstrates Safety, Efficacy in Treating Perimenstrual Migraine

Absence of photophobia, phonophobia, and nausea were achieved in a similar percentage of perimenstrual and non-perimenstrual ubrogepant-treated attacks.

Higher Dose OnabotulinumtoxinA Safe for Chronic Migraine in Real-World Study

These real-world findings confirm that a 156- to 195-unit dose of onabotulinumtoxinA is efficacious and safe, consistent with findings from the PREEMPT clinical trials.

STOP 301 Study of INP104 for Migraine: Carrie Dougherty, MD, FAHS

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the findings of the STOP 301 study.

External Trigeminal Nerve Stimulation Proves Safety, Efficacy in Migraine Treatment

Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.

Collecting Drug-Drug Interaction Data on Rimegepant: Elyse Stock, MD

The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.

Early Response to Eptinezumab Predicts Continued Response in Chronic Migraine

An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.

Real-World Use of CGRPs in Combination With OnabotulinumtoxinA: Andrew M. Blumenfeld, MD

The director of the Headache Center of Southern California discussed his research from AHS 2021 which evaluated safety and efficacy of combined treatment with CGRPs and onabotulimtoxinA.

Combination GCRP Monoclonal Antibody and Gepant Treatment Shows Safety, Efficacy

Open-label data of concomitant use of CGRP monoclonal antibodies and receptor antagonists suggest that the agents can be safely and effectively combined in the treatment of migraine.

Nearly Half of Patients With Migraine Hesitate to Seek Care

The reported reasons included wanting to take care of symptoms themselves, concern that migraine will not be taken seriously, and believing migraines are not severe or painful enough to seek care.

Eptinezumab Reduces Severity, Burdensome Features of Headache Episodes

Treatment with eptinezumab resulted in reduced burdensome features of headache episodes including severe pain, photophobia, phonophobia, nausea, and limited physical activity.

Survey Suggests Need for Migraine Treatment Standardization Among Women’s Healthcare Providers

Respondents reported varying levels of comfort regarding the management of migraine during pregnancy, with only half of women’s healthcare providers indicating they conducted counseling on migraine during pregnancy.

Lasmiditan Efficacious in Patients With Insufficient Triptan Response

Investigators’ analysis of a subset of patients with insufficient response from the CENTURION study suggests that the acute agent from Eli Lilly offers potential in this population.

INP104 Continues to Show Promising Efficacy in Acute Migraine Treatment

Treatment with INP104 was associated with high rates of symptoms freedom and may be a promising new acute treatment for patients with migraine.

Consensus Reached on Updates for ICHD-3 Criteria for Posttraumatic Headache

Experts were in agreement that the criteria should include PTH phenotype, TBI mechanism and TBI comorbidities.

Intranasal DHE Agent INP104 Displays Safety for Migraine Treatment

The nasal delivery of dihydroergotamine also showed a lower incidence of nausea than IV-administrated dihydroergotamine.

Rimegepant, Ubrogepant, Lasmiditan All Safe and Effective for Acute Migraine Treatment

Rimegepant (Nurtec ODT; Biohaven) had the lowest number needed to treat for sustained pain freedom from migraine.

Atogepant Sustains 1-Year Efficacy in Migraine in Extension Trial

ATA188’s Potential in Progressive MS: Jakob Dupont, MD, MA

The head of global research and executive vice president of Atara Biotherapeutics discussed improvements seen in patients treated with the investigational therapy.

Developing the aT2-LV Biomarker for Progressive MS

Robert Zivadinov, MD, PhD, professor of neurology and director of the Buffalo Neuroimaging Analysis Center, discussed the post-hoc analysis of the ORATORIO trial he and colleagues conducted.

What to Expect From the 2021 American Headache Society Annual Scientific Meeting

With the AHS 63rd Annual Scientific Meeting set to kick-off virtually on June 3, 2021, Jessica Ailani, MD, FAHS, offered her perspective on what to expect from the presentations and sessions.

Living Up to the Gold Standard in Parkinson Disease: Jennifer S. Hui, MD

The assistant professor of neurology at the Keck School of Medicine at University of Southern California discussed the importance of having additional agents to treat Parkinson disease.

Remotely Screening and Evaluating Cognitive Impairment

Richard Gershon, PhD, vice chair for research at the Northwestern University Feinberg School of Medicine, discussed the development of the mobile toolbox battery to track cognitive decline.

Evaluating ATA188 in Progressive MS: Jakob Dupont, MD, MA

The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.

Evaluating the aT2-LV Biomarker for MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the findings of the post-hoc analysis of the ORATORIO study.